

# 台灣癌症登記中心通知

急件

發件人：台灣癌症登記中心  
電話：02-2351-1708  
傳真：02-2351-1733  
地址：100 台北郵政 84-310 信箱  
日期：112 年 3 月 9 日  
編號：癌登第 112003 號

收文者：所有申報醫院

副本收文者：衛生福利部國民健康署、台灣癌症登記學會、資拓宏宇國際股份有限公司

主 題：因應癌症登記實務作業之需求，適用2022診斷年以後個案申報規則，請貴院依說明段辦理

☒ 急件      ☒ 請檢閱      ☐ 請加註      ☐ 請回覆      ☐ 請回收

- 
- 一、 本案係依衛生福利部國民健康署委託「台灣癌症登記工作計畫」辦理。
  - 二、 因應癌登第 111006 號通知文第五點所述，修訂甲狀腺癌 Solid Tumor Rules (Other Sites)，請詳見附件 1。
  - 三、 針對 2022 診斷年起，個案組織型態新增代碼申報原則，摘錄如下：
    - (1) Clear cell papillary renal cell **carcinoma** (C64.9)編碼為 8323/1 (WHO classification of tumours 4<sup>th</sup>)，**無需申報**。因避免 carcinoma 敘述產生誤會，在新版 WHO classification of tumours 5<sup>th</sup> 已更名為 Clear cell papillary renal cell **tumour**。
    - (2) Low-grade appendiceal mucinous neoplasm (LAMN) (C18.1) [Beginning with cases diagnosed 1/1/2022 forward, LAMN should be assigned a behavior code of /2] Note: Effective 1/1/2022, LAMN becomes reportable and is coded 8480/2, unless the pathologist indicates invasive behavior, which is coded 8480/3. 即從 2022 年 1 月 1 日起新診斷 Low-grade appendiceal mucinous neoplasm (LAMN) (C18.1)個案，編碼 8480/2，**需申報**。[更新癌登第 107004 號通知文第二、(2)]

(3) Adult granulosa cell tumor of **ovary** (C56.9)編碼由 8620/1 變為 8620/3，需申報。Adult granulosa cell tumor of **testis** (C62.\_) 仍維持 8620/1，無需申報。

(4) Gastroblastoma (C16.\_)編碼由 8976/1 變為 8976/3，需申報。

四、近年依據 WHO Classification of Tumours 第 5 版所彙整最新病理組織型態編碼表，統整適用於 2022 診斷年以後個案之新增修訂處(附件二)與所有新增修訂處彙整表(附件三)，提供參考。

## 附件 1.

### 修訂甲狀腺癌 STR RULE (Other Sites)：

甲狀腺癌 Papillary thyroid microcarcinoma (PTmC) (M-code 8341/3)是指腫瘤大小一公分以下( $\leq 1$  cm)的 Papillary thyroid carcinoma，非為特殊的組織型態亞型。

① 若病理報告描述甲狀腺僅有一顆 papillary microcarcinoma，且其細胞並沒有其他 variants，應編碼為 8341/3，非申報為 8260/3。(同步修正 STR Other Sites H17)

Rule H17	<p>Code <b>papillary microcarcinoma of thyroid</b> to <b>papillary microcarcinoma 8341</b>.</p> <p>Note: For thyroid primaries only, the term micropapillary/papillary microcarcinoma does not refer to a specific histologic type. In North America, it means the papillary component of the tumor is minimal or occult.</p> <p>We concur with the statement above; however, it should be noted that not all cases of thyroid cancer from Taiwan report tumor size. Therefore, we continue to use the morphology code 8341 to differentiate very small or occult papillary adenocarcinoma according to the <i>WHO Classification of Tumours of Endocrine Organs</i>.</p>
----------	---

② 若病理報告描述甲狀腺多顆且均為 papillary microcarcinoma，且其細胞並沒有其他 variants 時，仍編碼為 8341/3。(同步修正 STR Other Sites H29)

Rule H29	<p>Code <b>multiple papillary microcarcinomas of thyroid</b> to <b>papillary microcarcinoma 8341</b>.</p> <p>Note: For thyroid primaries only, the term micropapillary/papillary microcarcinoma does not refer to a specific histologic type. In North America, it means the papillary component of the tumor is minimal or occult.</p> <p>We concur with the statement above; however, it should be noted that not all cases of thyroid cancer from Taiwan report tumor size. Therefore, we continue to use the morphology code 8341 to differentiate very small or occult papillary adenocarcinoma according to the <i>WHO Classification of Tumours of Endocrine Organs</i>.</p>
----------	---

③ 若病理報告描述甲狀腺多顆，且包含 Papillary thyroid carcinoma (tumor $>1$ cm) 及 Papillary microcarcinoma ( $\leq 1$  cm)時，其組織型態應編碼為 Papillary thyroid carcinoma 8260/3。

附件 2. 摘錄適用於 2022 診斷年以後個案之新增修訂處

Status	ICD-O-3	Term
New term	8013/3	<b>Combined</b> large cell neuroendocrine carcinoma (C57.9, <b>C60-C68</b> )
New term	8031/3	Giant cell <b>urothelial</b> carcinoma (C65.9, C66.9, C67._, C68._)
New term	8045/3	Combined small cell <b>neuroendocrine</b> carcinoma (C57.9, <b>C60-C68</b> )
New term	8051/3	Verrucous carcinoma ( <b>including carcinoma cuniculatum</b> ) (C60._, <b>C63.2</b> )
New code and term	<b>8054/3</b>	<b>Warty carcinoma</b> (C60._, <b>C63.2</b> ) [originally 8051/3]
New code and term	<b>8054/3</b>	<b>Condylomatous carcinoma</b> (C60._, <b>C63.2</b> ) [originally 8051/3]
New behavior code and term	8071/2	<b>Differentiated-type vulvar intraepithelial neoplasia</b> (C51._) <b>Differentiated exophytic vulvar intraepithelial lesion</b> (C51._) <b>Vulvar acanthosis with altered differentiation</b> (C51._) <b>Differentiated penile intraepithelial neoplasia</b> (C60._) [ <b>HPV-independent</b> ]
New term	8077/2	<b>Penile</b> intraepithelial neoplasia (C60._) <b>High-grade squamous intraepithelial lesion</b> (C60._) [ <b>HPV-associated</b> ]
New term	8082/3	Lymphoepithelioma-like <b>urothelial</b> carcinoma (C65.9, C66.9, C67._, C68._)
New code and term	<b>8085/3</b>	<b>Squamous cell carcinoma, HPV-positive</b> (C01.9, C02.4, C05.1, C05.2, C09._, C10._, C31._) <b>Squamous cell carcinoma, HPV-associated</b> (C51._, C52.9, C53._, <b>C60._, C63.2</b> )
New code and term	<b>8086/3</b>	<b>Squamous cell carcinoma, HPV-negative</b> (C01.9, C02.4, C05.1, C05.2, C09._, C10._, C31._) <b>Squamous cell carcinoma, HPV-independent</b> (C51._, C52.9, C53._) <b>Squamous cell carcinoma, usual type</b> (C60._, <b>C63.2</b> ) [ <b>HPV-independent</b> ]
New term	8120/3	<b>Squamotransitional cell carcinoma</b> (C53._) <b>Conventional</b> urothelial carcinoma (C65.9, C66.9, C67._, C68._) Urothelial carcinoma <b>with squamous differentiation</b> (C65.9, C66.9, C67._, C68._) Urothelial carcinoma <b>with glandular differentiation</b> (C65.9, C66.9, C67._, C68._) Urothelial carcinoma <b>with trophoblastic differentiation</b> (C65.9, C66.9, C67._, C68._) <b>Nested</b> urothelial carcinoma (C65.9, C66.9, C67._, C68._) <b>Large nested</b> urothelial carcinoma (C65.9, C66.9, C67._, C68._) <b>Tubular and microcystic</b> urothelial carcinomas (C65.9, C66.9, C67._, C68._) <b>Lipid-rich</b> urothelial carcinoma (C65.9, C66.9, C67._, C68._) <b>Clear cell (glycogen-rich)</b> urothelial carcinoma (C65.9, C66.9, C67._, C68._) <b>Sarcomatoid</b> urothelial carcinoma (C65.9, C66.9, C67._, C68._) [原申報 8122/3]
New term	8122/3	<b>Plasmacytoid</b> urothelial carcinoma (C65.9, C66.9, C67._, C68._)
New term	8130/2	Non-invasive papillary urothelial carcinoma, <b>low grade</b> (C65.9, C66.9, C67._, C68._) <b>Low-grade</b> papillary urothelial carcinoma <b>with an inverted growth pattern</b> (C65.9, C66.9, C67._, C68._) Non-invasive papillary urothelial carcinoma, <b>high grade</b> (C65.9, C66.9, C67._, C68._) Non-invasive <b>high-grade</b> papillary urothelial carcinoma <b>with an inverted growth pattern</b> (C65.9, C66.9, C67._, C68._)

Status	ICD-O-3	Term
New term	8140/3	Endolymphatic sac tumor (C30.1) Parathyroid carcinoma (C75.0) Carcinoma of Skene, Cowper and Littre glands (C52.9, C68.0) Acinar adenocarcinoma of prostate (C61.9) Pleomorphic giant cell acinar adenocarcinoma (C61.9) Prostatic intraepithelial neoplasia--like carcinoma (C61.9)
New term	8147/3	Adenoid cystic (basal cell) carcinoma (C61.9)
New term	8148/2	Prostatic intraepithelial neoplasia, high-grade (C61.9)
New term	8154/3	Mixed neuroendocrine non-neuroendocrine neoplasm (MiNEN) (C15-C26, C60-C68)
New term	8272/3	Pituitary adenoma / pituitary neuroendocrine tumor (PitNET) (C75.1)
New code and term	8311/3	Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome-associated renal cell carcinoma (C64.9) MiT family translocation renal cell carcinomas (C64.9) Eosinophilic solid and cystic renal cell carcinomas (C64.9) TFE3-rearranged renal cell carcinomas (C64.9) TFEB-altered renal cell carcinomas (C64.9) ELOC (formerly TCEB1)-mutated renal cell carcinomas (C64.9) Fumarate hydratase-deficient renal cell carcinomas (C64.9) ALK-rearranged renal cell carcinomas (C64.9) Succinate dehydrogenase-deficient renal cell carcinoma (C64.9)
<del>New term</del>	<del>8312/3</del>	<del>Succinate dehydrogenase-deficient renal carcinoma (C64.9)</del> 改申報 8311/3
Behavior code change (3→1)	8323/1	Clear cell papillary renal cell carcinoma (C64.9) [MP/H 8255/3→8323/1] >> Clear cell papillary renal cell tumour (C64.9) [WHO Blue books 5 <sup>th</sup> - terminology change]
Behavior code change (1→2)	8480/2	Low-grade appendiceal mucinous neoplasm (LAMN) (C18.1) [Beginning with cases diagnosed 1/1/2022 forward, LAMN should be assigned a behavior code of /2] Note: Effective 1/1/2022, LAMN becomes reportable and is coded 8480/2, unless the pathologist indicates invasive behavior, which is coded 8480/3.
New behavior code and term	8480/2	High-grade appendiceal mucinous neoplasm (C18.1) Note: Effective 1/1/2022, HAMN can be either /2 or /3 depending on the pathologist statement of behavior.
New term	8510/3	Renal medullary carcinoma (C64.9) SMARCB1-deficient medullary-like renal cell carcinoma (C64.9) SMARCB1-deficient undifferentiated renal cell carcinoma, NOS (C64.9) SMARCB1-deficient dedifferentiated renal cell carcinomas of other specific subtypes (C64.9)
Behavior code change (1→3)	8620/3	Adult granulosa cell tumor of ovary (C56.9)
New term	8620/1	Adult granulosa cell tumor of testis (C62._)

Status	ICD-O-3	Term
Behavior code change (1→3)	8693/3	Extra-adrenal paraganglioma, NOS (C17._, C24.1, <b>C60-C68</b> ) Nonchromaffin paraganglioma, NOS Chemodectoma
New term	8693/3	Vagal paraganglioma (C75.5) Laryngeal paraganglioma (C75.5) Sympathetic paragangliomas (C75.5) <b>Composite</b> paraganglioma (C75.5) Paraganglioma (C73.9, C75.1) <b>Cauda equina neuroendocrine tumour (previously paraganglioma) (C72._)</b>
New code and term	8714/3	<b>Neoplasms with perivascular epithelioid cell differentiation (PEComa) NOS, malignant (C15-C26, C34._, C47._, C49._, <del>C54._,</del> C60-C68)</b> <b>Perivascular epithelioid cell tumour, malignant (C65.9, C66.9, C67._, C68._)</b> <b>Perivascular epithelioid tumour, malignant (C47._, C49._, C54._)</b>
New term	8963/3	<b>Extra-renal rhabdoid tumour (C47._, C49._, <b>C60-C68</b>)</b>
New code and term <b>Behavior code change (1→3)</b>	8976/3	<b>Gastroblastoma (C16._) [Beginning with cases diagnosed 1/1/2022 forward, Gastroblastoma should be assigned a behavior code of /3]</b>
New behavior code and term	9061/2	<b>Intratubular</b> seminoma (C62._) <b>Intratubular trophoblast</b> (C62._)
New term	9061/3	Seminoma <b>with syncytiotrophoblastic cells</b> (C62._)
New behavior code and term	9070/2	<b>Intratubular</b> embryonal carcinoma (C62._)
New behavior code and term	9071/2	<b>Intratubular</b> yolk sac tumour (C62._)
New term	9071/3	Yolk sac tumor, <b>pre-pubertal type</b> (C52.9, <b>C62._</b> ) <b>Yolk sac tumor, postpubertal-type (C62._)</b>
Behavior code change (3→1)	9080/1	Immature teratoma (C34._) Immature teratoma (C37.9) Immature teratoma ( <b>grade 2</b> ) ( <b>C73.9</b> )
New behavior code and term	9080/2	<b>Intratubular</b> teratoma (C62._)
New term	9080/3	Teratoma, <b>postpubertal-type</b> (C62._)
New term	9084/0	<b>Teratoma, prepubertal-type (C62._)</b>
New term	9084/3	<b>Germ cell tumours with somatic-type solid malignancy (C37.9)</b> <b>Teratoma with carcinoid (neuroendocrine tumour) (C64.9)</b> <b>Teratoma with somatic-type malignancy (C62._)</b>
New term	9085/3	Mixed teratoma-yolk sac tumor (C64.9) <b>Polyembryoma (C62._)</b> <b>Diffuse embryoma (C62._)</b> <b>Mixed teratoma and yolk sac tumour, prepubertal-type (C62._)</b>

Status	ICD-O-3	Term
New behavior code and term	9104/3	Placental site trophoblastic tumour <b>of the testis (C62._)</b>
New term	9120/3	<b>Postradiation</b> angiosarcoma (C50._) <b>Epithelioid</b> angiosarcoma (C50._, <b>C60-C68</b> )
New code and term <b>(revised)</b>	<b>9385/3</b>	<b>Diffuse midline glioma, H3 K27-altered <del>M-mutant</del> (C71._)</b> <b>Diffuse hemispheric glioma, H3 G34-mutant (C71._)</b> <b>Diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype (C71._)</b> <b>Infant-type hemispheric glioma (C71._)</b>
New term	9391/3	Ependymoma, NOS ( <b>C57._</b> ) <b>Supratentorial</b> ependymoma, NOS (C71._) <b>Posterior fossa</b> ependymoma, NOS (C71._) <b>Spinal</b> ependymoma, NOS (C71._, <b>C72.0</b> )
New code and term	<b>9396/3</b>	<b>Ependymoma, RELA fusion-positive (C71._)</b> <b>Supratentorial ependymoma, ZFTA fusion-positive / YAP1 fusion-positive (C71._)</b> <b>Posterior fossa group A (PFA) / group B (PFB) ependymoma (C71._)</b> <b>Spinal ependymoma, MYCN-amplified (C71._, C72.0)</b>
New term <b>(revised)</b>	9400/3	<del>Diffuse</del> astrocytoma, IDH-mutant, <b>grade 2 /IDH-wildtype</b> (C71._)
New term <b>(revised)</b>	9401/3	<del>Anaplastic</del> astrocytoma, IDH-mutant, <b>grade 3 /IDH-wildtype</b> (C71._)
New behavior code and term	9421/3	<b>High-grade</b> astrocytoma with piloid features (C71._)
New term	9430/3	Astroblastoma, <b>MN1-altered</b> (C71._)
New code and term	<b>9445/3</b>	<b>Glioblastoma, IDH-mutant (C71._)</b> <b>Astrocytoma, IDH-mutant, grade 4 (C71._)</b>
New term <b>(revised)</b>	9450/3	Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, <b>grade 2 (C71._)</b>
New term <b>(revised)</b>	9451/3	<del>Anaplastic</del> oligodendroglioma, IDH-mutant and 1p/19q-codeleted, <b>grade 3 (C71._)</b>
New term	9470/3	Medulloblastoma, <b>classic</b> (C71._) <b>Medulloblastoma, histologically defined (C71._)</b>
New term <b>(revised)</b>	9473/3	<b>CNS embryonal tumour, <del>NEC</del>/NOS (C71._)</b>
New term	9480/3	<b>Primary intracranial</b> sarcoma, DICER1-mutant (C71._)
New term	9500/3	<b>CNS</b> neuroblastoma, <b>FOXR2-activated (C71._)</b> <b>CNS tumour with BCOR internal tandem duplication (C71._)</b>
New behavior code and term	9509/3	<b>Diffuse leptomeningeal</b> glioneuronal tumor (C71._)



Status	ICD-O-3	Term
New term	8010/3	<b>Urachal</b> carcinoma (C65.9, C66.9, C67._, C68._)
New term	8013/3	<b>Combined</b> large cell neuroendocrine carcinoma (C57.9, C60-C68)
New term	8020/3	Carcinoma, <b>poorly differentiated</b> , NOS (C51._) Poorly differentiated urothelial carcinoma (C65.9, C66.9, C67._, C68._) <b>Anaplastic thyroid</b> carcinoma (C73.9)
New code and term	<b>8023/3</b>	<b>NUT carcinoma (C30.0, C31._, C34._, C37.9)</b>
New term	8031/3	Giant cell <b>urothelial</b> carcinoma (C65.9, C66.9, C67._, C68._)
New term	8033/3	Carcinoma <b>with</b> sarcomatoid <b>component (C18._, C19.9, C20.9)</b>
New term	8035/3	<b>Squamous cell</b> carcinoma with osteoclast-like giant cells (C44._)
New term	8041/3	<b>High-grade</b> neuroendocrine carcinoma (C54._, C55.9)
New term	8041/3	Neuroendocrine carcinoma, <b>poorly differentiated</b> (C50._)
New term	8041/3	Small cell carcinoma, <b>pulmonary type (C56.9)</b>
New term	8044/3	Small cell carcinoma, <b>hypercalcaemic type (C56.9)</b> Small cell carcinoma, <b>large cell variant (C56.9)</b> <b>Thoracic SMARCA4-deficient undifferentiated tumour (C34._)</b>
New term	8045/3	Combined small cell <b>neuroendocrine</b> carcinoma (C57.9, C60-C68)
New term	8051/3	Verrucous carcinoma ( <b>including carcinoma cuniculatum</b> ) (C60._, C63.2)
New code and term	<b>8054/3</b>	<b>Warty carcinoma (C60._, C63.2) [originally 8051/3]</b>
New code and term	<b>8054/3</b>	<b>Condylomatous carcinoma (C60._, C63.2) [originally 8051/3]</b>
New behavior code and term	8071/2	<b>Differentiated-type vulvar intraepithelial neoplasia (C51._)</b> <b>Differentiated exophytic vulvar intraepithelial lesion (C51._)</b> <b>Vulvar acanthosis with altered differentiation (C51._)</b> <b>Differentiated penile intraepithelial neoplasia (C60._) [HPV-independent]</b>
New term	8071/3	<b>Keratoacanthoma</b> (C44._, C69.0)
New term	8074/3	<b>Pseudovascular</b> squamous cell carcinoma (C44._)
New term	8077/2	<b>Penile</b> intraepithelial neoplasia (C60._) High-grade squamous intraepithelial <b>lesion (C60._) [HPV-associated]</b>
New term	8077/2	Oral epithelial dysplasia, high grade (C00._, C02._, C03._, C04._, C05._, C06._)
New term	8082/3	Lymphoepithelioma-like <b>urothelial</b> carcinoma (C65.9, C66.9, C67._, C68._)



Status	ICD-O-3	Term
New code and term	8085/3	<b>Squamous cell carcinoma, HPV-positive (C01.9, C02.4, C05.1, C05.2, C09._, C10._, C31._)</b> <b>Squamous cell carcinoma, HPV-associated (C51._, C52.9, C53._, C60._, C63.2)</b>
New code and term	8086/3	<b>Squamous cell carcinoma, HPV-negative (C01.9, C02.4, C05.1, C05.2, C09._, C10._, C31._)</b> <b>Squamous cell carcinoma, HPV-independent (C51._, C52.9, C53._)</b> <b>Squamous cell carcinoma, usual type (C60._, C63.2) [HPV-independent]</b>
New term	8090/3	Basal cell carcinoma with <b>adnexal differentiation</b> (C44._)
New term	8091/3	Superficial basal cell carcinoma (C44._)
New term	8092/3	Basal cell carcinoma with <b>sarcomatoid differentiation</b> (C44._)
New term	8098/3	Adenoid basal carcinoma ( <b>C52.9</b> )
New behavior code and term	8100/3	<b>Trichoblastic carcinoma/carcinosarcoma</b> (C44._)
New term	8120/3	<b>Squamotransitional cell carcinoma</b> (C53._) <b>Conventional</b> urothelial carcinoma (C65.9, C66.9, C67._, C68._) Urothelial carcinoma <b>with squamous differentiation</b> (C65.9, C66.9, C67._, C68._) Urothelial carcinoma <b>with glandular differentiation</b> (C65.9, C66.9, C67._, C68._) Urothelial carcinoma <b>with trophoblastic differentiation</b> (C65.9, C66.9, C67._, C68._) <b>Nested</b> urothelial carcinoma (C65.9, C66.9, C67._, C68._) <b>Large nested</b> urothelial carcinoma (C65.9, C66.9, C67._, C68._) <b>Tubular and microcystic</b> urothelial carcinomas (C65.9, C66.9, C67._, C68._) <b>Lipid-rich</b> urothelial carcinoma (C65.9, C66.9, C67._, C68._) <b>Clear cell (glycogen-rich)</b> urothelial carcinoma (C65.9, C66.9, C67._, C68._) <b>Sarcomatoid</b> urothelial carcinoma (C65.9, C66.9, C67._, C68._) <b>[原申報 8122/3]</b>
New term	8122/3	<b>Plasmacytoid</b> urothelial carcinoma (C65.9, C66.9, C67._, C68._)
New term	8130/2	Non-invasive papillary urothelial carcinoma, <b>low grade</b> (C65.9, C66.9, C67._, C68._) <b>Low-grade</b> papillary urothelial carcinoma <b>with an inverted growth pattern</b> (C65.9, C66.9, C67._, C68._) Non-invasive papillary urothelial carcinoma, <b>high grade</b> (C65.9, C66.9, C67._, C68._) Non-invasive <b>high-grade</b> papillary urothelial carcinoma <b>with an inverted growth pattern</b> (C65.9, C66.9, C67._, C68._)
New term	8140/3	<b>Endolymphatic sac tumor (C30.1)</b> <b>Parathyroid carcinoma (C75.0)</b> <b>Carcinoma of Skene, Cowper and Littre glands (C52.9, C68.0)</b> <b>Acinar</b> adenocarcinoma of <b>prostate</b> (C61.9) <b>Pleomorphic giant cell acinar</b> adenocarcinoma (C61.9) <b>Prostatic intraepithelial neoplasia--like</b> carcinoma (C61.9)
New behavior code and term	8144/2	<b>Intestinal-type adenoma, high grade (C16._, C17._, C24.1)</b> <b>Sporadic intestinal-type gastric adenoma (C16._)</b> <b>Syndromic intestinal-type gastric adenoma (C16._)</b>

Status	ICD-O-3	Term
New term	8144/3	Enteric adenocarcinoma (C34._, C65.9, C66.9, C67._, C68._) Adenocarcinoma, intestinal type ( <b>C51._</b> ) <b>Mucinous</b> carcinoma, intestinal type ( <b>C53._</b> )
New term	8147/3	<b>Adenoid cystic</b> (basal cell) carcinoma (C61.9)
New term	8148/2	Prostatic intraepithelial neoplasia, <b>high-grade</b> (C61.9)
Behavior code change (0→3)	8150/3	Islet cell adenoma (C25._) Islet cell adenomatosis (C25._) Nesidioblastoma (C25._)
Behavior code change (1→3)	8150/3	Islet cell tumor, NOS (C25._) Pancreatic endocrine tumor, NOS (C25._)
New term	8150/3	<b>Oncocytic neuroendocrine</b> tumor, non-functioning pancreatic (C25._) <b>Pleomorphic neuroendocrine</b> tumor, non-functioning pancreatic (C25._) <b>Clear cell neuroendocrine</b> tumor, non-functioning pancreatic (C25._) <b>Cystic neuroendocrine</b> tumor, non-functioning pancreatic (C25._)
Behavior code change (0→3)	8151/3	Insulinoma (C25._) Beta cell adenoma (C25._)
Behavior code change (1→3)	8152/3	Glucagonoma (C25._) Pancreatic peptide and pancreatic peptide-like peptide within terminal tyrosine amide producing tumor (C25._) L-cell tumor (C18._, C19.9, C20.9, C25._) Glucagon-like peptide-producing tumor (C18._, C19.9, C20.9, C25._) PP/PYY producing tumor (C18._, C19.9, C20.9, C25._)
Behavior code change (1→3)	8153/3	Gastrinoma (C16._, C17._, C24.1, C25._) G cell tumor Gastrin cell tumor
New term	8154/3	Mixed ductal- <b>neuroendocrine</b> carcinomas (C25._)
New term	8154/3	Mixed acinar- <b>neuroendocrine</b> carcinomas (C25._)
New term	8154/3	Mixed <b>neuroendocrine non-neuroendocrine neoplasm (MiNEN)</b> (C15-C26, C60-C68)
Behavior code change (1→3)	8155/3	VIPoma (C25._)
Behavior code change (1→3)	8156/3	Somatostatinoma (C16._, C17._, C24.1, C25._) Somatostatin cell tumor
New behavior code and term	8158/3	ACTH-producing tumour with Cushing syndrome (C25._)
Behavior code change (1→3)	8158/3	ACTH-producing tumour (C25._) Endocrine tumor, functioning, NOS

Status	ICD-O-3	Term
New term	8160/3	Large duct intrahepatic cholangiocarcinoma (C22.1) Small duct intrahepatic cholangiocarcinoma (C22.1)
New term	8163/2	Intra-ampullary papillary-tubular neoplasm (C17._, C24.1)
New term	8174/3	Hepatocellular carcinoma, steatohepatitis (C22.0) Hepatocellular carcinoma, macrotrabecular massive (C22.0) Hepatocellular carcinoma, chromophobe (C22.0) Hepatocellular carcinoma, neutrophil-rich (C22.0) Hepatocellular carcinoma, lymphocyte-rich (C22.0)
New term	8200/3	<b>Thymic carcinoma</b> with adenoid cystic carcinoma-like features ( <b>C37.9</b> )
New term	8200/3	<b>Classic</b> adenoid cystic carcinoma (C50._) <b>Solid-basaloid</b> adenoid cystic carcinoma (C50._) Adenoid cystic carcinoma with <b>high-grade transformation</b> (C50._)
New term	8210/2	Adenomatous polyp, <b>high-grade dysplasia</b> (C16._, C17._, C18._, C19.9, C20.9, C24.1)
New behavior code and term	8211/2	Tubular adenoma, <b>high grade</b> ( <b>C18._, C19.9, C20.9</b> )
New behavior code and term	8213/2	Serrated <b>dysplasia, high grade</b> ( <b>C16._, C17._, C18._, C19.9, C20.9, C24.1</b> ) <b>Intestinal-type dysplasia</b> (C16._) <b>Foveolar-type (gastric-type) dysplasia</b> (C16._) <b>Gastric pit/crypt dysplasia</b> (C16._) <del><b>Hyperplastic polyp, microvesicular type</b> (C18._, C19.9, C20.9)</del> <del><b>Hyperplastic polyp, goblet cell</b> (C18._, C19.9, C20.9)</del>
New term	8240/3	Neuroendocrine tumor, <b>NOS</b> (C51._, C57.9)
Behavior code change (1→3)	8241/3	Carcinoid tumor, argentaffin
New term	8241/3	Serotonin-producing <b>tumour with and without carcinoid syndrome</b> (C25._)
Behavior code change (1→3)	8242/3	Enterochromaffin-like cell carcinoid, NOS ECL cell carcinoid, NOS
New term	8243/3	Goblet cell <b>adenocarcinoma</b> ( <b>C18.1</b> )
New term	8249/3	Neuroendocrine tumor, <b>grade 3</b> (C15-C26)
New behavior code and term	8250/2	<b>Adenocarcinoma in situ, non-mucinous</b> ( <b>C34._</b> )
New term	8250/3	<b>Lepidic</b> adenocarcinoma ( <b>C34._</b> )
New behavior code and term	8253/2	<b>Adenocarcinoma in situ, mucinous</b> ( <b>C34._</b> )
New term	8253/3	<b>Invasive</b> mucinous <b>adenocarcinoma</b> ( <b>C34._</b> )
New term	8254/3	Mixed <b>invasive</b> mucinous and non-mucinous <b>adenocarcinoma</b> ( <b>C34._</b> )

Status	ICD-O-3	Term
New code and term	<b>8256/3</b>	<b>Minimally invasive adenocarcinoma, non-mucinous (C34._)</b>
New code and term	<b>8257/3</b>	<b>Minimally invasive adenocarcinoma, mucinous (C34._)</b>
New term	8260/3	<b>Low-grade</b> papillary adenocarcinoma (C37.9)
New term	8261/2	Villous adenoma, <b>high grade (C18._, C19.9, C20.9)</b>
New term	8262/3	<b>Adenoma-like</b> adenocarcinoma (C18._, C19.9, C20.9)
New term	8263/2	Tubulovillous adenoma, <b>high grade (C18._, C19.9, C20.9)</b>
New term	8263/3	<b>Endometrioid</b> adenocarcinoma, <b>villoglandular (C54._, C55.9)</b>
New term	8263/3	<b>Villoglandular</b> carcinoma (C53._)
New term	8265/3	Micropapillary adenocarcinoma (C18._, C19.9, C20.9, C34._)
New term	8272/3	Pituitary <b>adenoma</b> / pituitary <b>neuroendocrine tumor (PitNET) (C75.1)</b>
New code and term	<b>8273/3</b>	<b>Pituitary blastoma (C75.1)</b>
New term	8310/3	Adenocarcinoma, <b>HPV-independent</b> , clear cell type (C53._) <b>Hyalinizing</b> clear cell carcinoma (C34._) Clear cell renal cell carcinoma (C64.9)
New code and term	<b>8311/3</b>	<b>Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome-associated renal cell carcinoma (C64.9)</b> <b>MiT family translocation renal cell carcinomas (C64.9)</b> <b>Eosinophilic solid and cystic renal cell carcinomas (C64.9)</b> <b>TFE3-rearranged renal cell carcinomas (C64.9)</b> <b>TFEB-altered renal cell carcinomas (C64.9)</b> <b>ELOC (formerly TCEB1)-mutated renal cell carcinomas (C64.9)</b> <b>Fumarate hydratase-deficient renal cell carcinomas (C64.9)</b> <b>ALK-rearranged renal cell carcinomas (C64.9)</b> <b>Succinate dehydrogenase-deficient renal cell carcinoma (C64.9)</b>
New term	8312/3	<del><b>Succinate dehydrogenase-deficient renal carcinoma (C64.9)</b></del> 改申報 8311/3
New term	8316/3	<b>Acquired</b> cystic <b>disease-associated</b> renal cell carcinoma (C64.9) <b>Tubulocystic</b> renal cell carcinoma (C64.9)
<b>Behavior code change (3→1)</b>	<b>8323/1</b>	<b>Clear cell papillary renal cell carcinoma (C64.9)</b> [MP/H 8255/3→8323/1] >> <b>Clear cell papillary renal cell tumour (C64.9)</b> [WHO Blue books 5 <sup>th</sup> - terminology change]
New term	8330/3	Follicular thyroid carcinoma (FTC), <b>widely invasive (C73.9)</b>
<b>Behavior code change (3→1)</b>	<b>8335/1</b>	<b>Follicular carcinoma, encapsulated (C73.9)</b>
New term	8337/3	<b>Poorly differentiated thyroid</b> carcinoma (C73.9)

Status	ICD-O-3	Term
New code and term	<b>8339/3</b>	<b>Follicular thyroid carcinoma (FTC), encapsulated angioinvasive (C73.9)</b>
New term	8342/3	<b>Oncocytic variant</b> of papillary thyroid carcinoma (PTC) (C73.9)
New term	8345/3	Medullary <b>thyroid</b> carcinoma (C73.9)
New code and term	<b>8349/1</b>	<b>Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (C73.9) [nonreportable]</b>
New behavior code and term	8380/2	<b>Atypical hyperplasia / Endometrioid intraepithelial neoplasia (C54._)</b> <b>Atypical hyperplasia of the endometrium (C54._)</b>
New term	8380/3	<b>POLE-ultramutated endometrioid carcinoma (C54._)</b> <b>Mismatch repair-deficient endometrioid carcinoma (C54._)</b> <b>p53-mutant endometrioid carcinoma (C54._)</b> <b>No specific molecular profile (NSMP) endometrioid carcinoma (C54._)</b>
New term	8390/3	Adnexal <b>adenocarcinoma</b> , NOS (C44._)
New term	8401/3	Apocrine carcinoma (C44._)
New term	8403/3	Malignant neoplasms arising from spiradenoma, <b>cylindroma</b> , or <b>spiradenocylindroma</b> (C44._)
New behavior code and term	8406/3	Syringocystadenocarcinoma papilliferum (C44._)
<b>Behavior code change (1→3)</b>	<b>8408/3</b>	<b>Aggressive digital papillary adenoma (C44._)</b>
New behavior code and term	8409/2	Porocarcinoma <b>in situ</b> (C44._)
New term	8430/3	<b>Sclerosing</b> mucoepidermoid carcinoma <b>with eosinophilia</b> (C73.9)
New behavior code and term	8441/2	Serous <b>tubal intraepithelial</b> carcinoma ( <b>C57.0</b> )
New behavior code and term	8441/2	Serous <b>endometrial intraepithelial</b> carcinoma ( <b>C54._</b> )
New term	8441/3	Serous cystadenocarcinoma, NOS ( <b>C25._</b> , C56.9)
New term	8452/1	Solid pseudopapillary tumour <b>of ovary (C56.9)</b>
New term	8452/3	Solid pseudopapillary neoplasm of the pancreas (C25._) Solid pseudopapillary neoplasm with high-grade carcinoma (C25._)
New code and term	<b>8455/2</b>	<b>Intraductal oncocytic papillary neoplasm, NOS (C25._)</b>
New code and term	<b>8455/3</b>	<b>Intraductal oncocytic papillary neoplasm with associated invasive carcinoma (C25._)</b>
New behavior code and term	8460/2	Serous <b>borderline tumour</b> - micropapillary variant ( <b>C56.9</b> )
New behavior code and term	8460/2	<b>Non-invasive low-grade</b> serous carcinoma ( <b>C56.9</b> )
New term	8460/3	<b>Low-grade</b> serous carcinoma (C48._, C56.9, C57._)
New term	8461/3	<b>High-grade</b> serous carcinoma (C48._, C56.9, C57._)
New term	8470/3	Mucinous cystadenocarcinoma NOS (C50._)

Status	ICD-O-3	Term
New code and term	<b>8474/3</b>	<b>Seromucinous carcinoma (C56.9)</b>
<b>Behavior code change (1→2)</b>	8480/2	<b>Low-grade</b> appendiceal mucinous neoplasm ( <b>LAMN</b> ) (C18.1) [Beginning with cases diagnosed 1/1/2022 forward, LAMN should be assigned a behavior code of /2] <b>Note:</b> Effective 1/1/2022, LAMN becomes reportable and is coded 8480/2, unless the pathologist indicates invasive behavior, which is coded 8480/3.
New behavior code and term	8480/2	<b>High-grade</b> appendiceal mucinous neoplasm (C18.1) <b>Note:</b> Effective 1/1/2022, HAMN can be either /2 or /3 depending on the pathologist statement of behavior.
New term	8480/3	Mucinous <b>tubular and spindle cell</b> carcinoma (C64.9)
New term	8482/3	Mucinous carcinoma, <b>gastric type</b> (C52.9, C53._) Adenocarcinoma, <b>HPV-independent, gastric type</b> (C53._)
New code and term	<b>8483/2</b>	<b>Adenocarcinoma in situ, HPV-associated (C53._)</b>
New code and term	<b>8483/3</b>	<b>Adenocarcinoma, HPV-associated (C52.9, C53._)</b>
New code and term	<b>8484/2</b>	<b>Adenocarcinoma in situ, HPV-independent (C53._)</b>
New code and term	<b>8484/3</b>	<b>Adenocarcinoma, HPV-independent, NOS (C53._)</b>
New term	8490/3	Signet ring cell/ <b>histiocytoid</b> carcinoma (C44._)
New term	8500/2	DCIS of <b>low nuclear grade</b> (C50._) DCIS of <b>intermediate nuclear grade</b> (C50._) DCIS of <b>high nuclear grade</b> (C50._)
New term	8500/3	<b>Adenocarcinoma of mammary gland type (C51._)</b> <b>Adenocarcinoma of anogenital mammary-like glands (C51._)</b>
New term	8502/3	Secretory carcinoma (C07._, C08._, C50._, C69.5)
New term	8503/2	Intraductal tubulopapillary neoplasm (C25._)
New term	8504/2	<b>Encapsulated papillary carcinoma (C50._)</b>
<b>Behavior code change (3→2)</b>	<b>8504/2</b>	<b>Intracystic carcinoma, NOS</b> <b>Intracystic papillary adenocarcinoma</b>
New term	8504/3	<b>Encapsulated papillary carcinoma with invasion (C50._)</b>
New behavior code and term	8507/3	<b>Invasive</b> micropapillary carcinoma ( <b>C50._</b> )
New code and term	<b>8509/2</b>	<b>Solid papillary carcinoma in situ (C50._)</b>
New code and term	<b>8509/3</b>	<b>Endocrine mucin-producing sweat gland carcinoma (C44._)</b> <b>Solid papillary carcinoma invasive (C50._)</b> <b>Tall cell carcinoma with reversed polarity (C50._)</b>

Status	ICD-O-3	Term
New term	8510/3	<b>Renal</b> medullary carcinoma (C64.9) <b>SMARCB1-deficient medullary-like renal cell carcinoma (C64.9)</b> <b>SMARCB1-deficient undifferentiated renal cell carcinoma, NOS (C64.9)</b> <b>SMARCB1-deficient dedifferentiated renal cell carcinomas of other specific subtypes (C64.9)</b>
New code and term	<b>8519/2</b>	<b>Pleomorphic lobular carcinoma in situ (C50._)</b>
New term	8520/2	<b>Florid</b> lobular carcinoma in situ (C50._)
New term	8551/3	Acinar <b>adenocarcinoma</b> (C34._)
New term	8560/3	Squamoid <b>eccrine ductal</b> carcinoma (C44._)
New term	8570/3	<b>Endometrioid carcinoma</b> with squamous differentiation (C54._)
New term	8570/3	<b>Low grade</b> adenosquamous carcinoma (C50._)
New term	8571/3	<b>Metaplastic carcinoma</b> with <b>chondroid</b> differentiation (C50._)
New term	8571/3	<b>Metaplastic carcinoma</b> with osseous differentiation (C50._)
New term	8572/3	<b>Fibromatosis-like</b> metaplastic carcinoma (C50._)
New term	8572/3	<b>Acinar</b> adenocarcinoma, <b>sarcomatoid</b> (C61.9)
New term	8576/3	<b>Paneth cell</b> carcinoma (C16._)
New term	8580/3	<b>Metaplastic</b> thymoma / <b>Sclerosing</b> thymoma (C37.9)
New term	8580/3	<b>Ectopic</b> thymoma (C73.9)
<b>Behavior code change (1→3)</b>	<b>8581/3</b>	<b>Type A</b> thymoma, including atypical variant (C37.9)
<b>Behavior code change (1→3)</b>	<b>8582/3</b>	<b>Type AB</b> thymoma (C37.9)
<b>Behavior code change (1→3)</b>	<b>8583/3</b>	<b>Type B1</b> thymoma (C37.9)
<b>Behavior code change (1→3)</b>	<b>8584/3</b>	<b>Type B2</b> thymoma (C37.9)
<b>Behavior code change (1→3)</b>	<b>8585/3</b>	<b>Type B3</b> thymoma (C37.9)
New term	8589/3	<b>Intrathyroid thymic</b> carcinoma (C73.9)
New code and term	<b>8594/1</b>	<b>Mixed germ cell-sex cord-stromal tumor, NOS (C56.9)</b>
<b>Behavior code change (1→3)</b>	<b>8620/3</b>	<b>Adult</b> granulosa cell tumor of <b>ovary</b> (C56.9)
New term	8620/1	<b>Adult</b> granulosa cell tumor of <b>testis</b> (C62._)
Behavior code change (1→3)	8680/3	Paraganglioma, NOS (C75.5)
Behavior code change (1→3)	8681/3	Sympathetic paraganglioma
Behavior code change (1→3)	8682/3	Parasympathetic paraganglioma



Status	ICD-O-3	Term
Behavior code change (1→3)	8690/3	Middle ear paraganglioma (C75.5) Glomus jugulare tumor, NOS (C75.5) Jugular paraganglioma (C75.5) Jugulotympanic paraganglioma (C75.5)
Behavior code change (1→3)	8691/3	Aortic body tumor (C75.5) Aortic body paraganglioma (C75.5) Aorticopulmonary paraganglioma (C75.5)
Behavior code change (1→3)	8692/3	Carotid body paraganglioma (C75.4) Carotid body tumor (C75.4)
Behavior code change (1→3)	8693/3	Extra-adrenal paraganglioma, NOS (C17._, C24.1, C60-C68) Nonchromaffin paraganglioma, NOS Chemodectoma
New term	8693/3	Vagal paraganglioma (C75.5) Laryngeal paraganglioma (C75.5) Sympathetic paragangliomas (C75.5) <b>Composite</b> paraganglioma (C75.5) Paraganglioma (C73.9, C75.1) <b>Cauda equina neuroendocrine tumour</b> (previously paraganglioma) (C72._)
Behavior code change (0→3)	8700/3	Pheochromocytoma (C74.1) Adrenal medullary paraganglioma (C74.1) Chromaffin paraganglioma Chromaffin tumor Chromaffinoma
New term	8700/3	<b>Composite</b> pheochromocytoma (C74.1)
New code and term	8714/3	<b>Neoplasms with perivascular epithelioid cell differentiation (PEComa) NOS, malignant (C15-C26, C34._, C47._, C49._, <del>C54._,</del> C60-C68)</b> <b>Perivascular epithelioid cell tumour, malignant (C65.9, C66.9, C67._, C68._)</b> <b>Perivascular epithelioid tumour, malignant (C47._, C49._, C54._)</b>
New term	8720/3	<b>Mucosal</b> melanoma (genital, oral, sinonasal)
New term	8721/3	<b>Mucosal</b> nodular melanoma (genital, oral, sinonasal)
New term	8743/3	<b>Low-CSD (cumulative sun damage)</b> melanoma (C44._)
New term	8744/3	Acral melanoma (C44._)
New term	8770/3	<b>Malignant Spitz tumor (Spitz melanoma)</b> (C44._)
New term	8780/3	<b>Melanoma</b> arising in blue nevus (C44._)

Status	ICD-O-3	Term
New term	8801/3	<b>Undifferentiated</b> spindle cell sarcoma (C47._, C49._)
New term	8802/3	<b>Undifferentiated</b> pleomorphic sarcoma (C47._, C49._) Pleomorphic <b>dermal</b> sarcoma (C44._)
New term	8803/3	<b>Undifferentiated</b> round cell sarcoma (C47._, C49._)
New term	8804/3	<b>Undifferentiated</b> epithelioid sarcoma (C47._, C49._) <b>Proximal or large cell</b> epithelioid sarcoma (C47._, C49._) <b>Classic</b> epithelioid sarcoma (C47._, C49._)
New term	8811/3	Myxofibrosarcoma (C47._, C49._) <b>Epithelioid</b> myxofibrosarcoma (C47._, C49._)
New behavior code and term	8825/3	<b>Low-grade</b> myofibriblastic <b>sarcoma</b> (C47._, C49._) Myofibroblastic <b>sarcoma</b> (C47._, C49._) Epithelioid inflammatory myofibroblastic sarcoma (C15-C26)
New term	8830/3	Undifferentiated high-grade pleomorphic sarcoma of <b>bone</b> (C40._, C41._)
<b>Behavior code change (3→1)</b>	<b>8832/1</b>	<b>Dermatofibrosarcoma protuberans (C47._, C49._)</b>
New term	8832/3	<b>Fibrosarcomatous</b> dermatofibrosarcoma protuberans (C47._, C49._) <b>Myxoid</b> dermatofibrosarcoma protuberans (C47._, C49._) Dermatofibrosarcoma protuberans <b>with myoid differentiation</b> (C47._, C49._) <b>Plaque-like</b> dermatofibrosarcoma protuberans (C47._, C49._)
<b>Behavior code change (3→1)</b>	<b>8833/1</b>	<b>Pigmented dermatofibrosarcoma protuberans (C44._, C47._, C49._)</b> <b>Bednar tumor (C44._)</b>
New term	8840/3	<b>Low-grade fibromyxoid sarcoma (C47._, C49._)</b> <b>Sclerosing epithelioid fibrosarcoma (C47._, C49._)</b>
New behavior code and term	8842/3	<b>Pulmonary myxoid sarcoma with EWSR1-CREB1 <del>translocation</del> fusion (C34._)</b> <b>Ossifying fibromyxoid tumour, malignant (C47._, C49._)</b>
New term	8854/3	<b>Epithelioid</b> liposarcoma (C47._, C49._)
New code and term	<b>8859/3</b>	<b>Myxoid pleomorphic liposarcoma (C47._, C49._)</b>
New term	8890/3	<b>Spindle</b> leiomyosarcoma (C54._) <b>Superficial</b> leiomyosarcoma (C60-C68) <b>Deep</b> leiomyosarcoma (C60-C68)
New term	8912/3	Sclerosing rhabdomyosarcoma <b>Congenital</b> spindle cell rhabdomyosarcoma <b>with VGLL2/NCOA2/CITED2 rearrangements</b> (C47._, C49._) <b>MYOD1-mutant</b> spindle cell / sclerosing rhabdomyosarcoma (C47._, C49._) <b>Intraosseous</b> spindle cell rhabdomyosarcoma ( <b>with TFCEP2/NCOA2 rearrangements</b> ) (C47._, C49._)
New term	8930/3	Endometrioid stromal sarcoma, high grade ( <b>C48._, C56.9</b> )

Status	ICD-O-3	Term
New term	8931/3	Endometrioid stromal sarcoma, low grade <b>(C48._, C56.9)</b>
New term	8936/3	<b>Extra-gastrointestinal stromal tumour (C48._)</b>
New term	8960/3	Wilms tumour <b>(C56.9)</b>
New term	8963/3	<b>Extra-renal rhabdoid tumour (C47._, C49._, C60-C68)</b>
New code and term <b>Behavior code change (1→3)</b>	<b>8976/3</b>	<b>Gastroblastoma (C16._) [Beginning with cases diagnosed 1/1/2022 forward, Gastroblastoma should be assigned a behavior code of /3]</b>
New behavior code and term	8983/3	Adenomyoepithelioma <b>with carcinoma (C50._)</b>
New term	8990/3	<b>Phosphaturic mesenchymal tumor, malignant</b> <b>NTRK-rearranged spindle cell neoplasm (emerging)</b>
New term	9020/3	<b>Periductal stromal tumor, low grade (C50._)</b>
New term	9044/3	<b>Dermal clear cell sarcoma (C44._)</b>
New code and term	<b>9045/3</b>	<b>Biphenotypic sinonasal sarcoma (C30.0, C31._)</b>
New behavior code and term	9050/2	Mesothelioma <b>in situ (C38.4)</b>
New term	9050/3	<b>Localized mesothelioma (C38.4)</b> <b>Diffuse mesothelioma, NOS (C38.4)</b>
New behavior code and term	9061/2	<b>Intratubular seminoma (C62._)</b> <b>Intratubular trophoblast (C62._)</b>
New term	9061/3	Seminoma <b>with syncytiotrophoblastic cells (C62._)</b>
New behavior code and term	9070/2	<b>Intratubular embryonal carcinoma (C62._)</b>
New behavior code and term	9071/2	<b>Intratubular yolk sac tumour (C62._)</b>
New term	9071/3	Yolk sac tumor, <b>pre-pubertal type (C52.9, C62._)</b> Yolk sac tumor, <b>postpubertal-type (C62._)</b>
Behavior code change (3→1)	9080/1	Immature teratoma (C34._) Immature teratoma (C37.9) Immature teratoma <b>(grade 2) (C73.9)</b>
New behavior code and term	9080/2	<b>Intratubular teratoma (C62._)</b>
New term	9080/3	Teratoma, <b>postpubertal-type (C62._)</b>
New term	9081/3	Teratocarcinosarcoma (C30.0, C31._)
New term	9084/0	<b>Teratoma, prepubertal-type (C62._)</b>
New term	9084/3	<b>Germ cell tumours with somatic-type solid malignancy (C37.9)</b> Teratoma <b>with carcinoid (neuroendocrine tumour) (C64.9)</b> Teratoma with somatic-type malignancy (C62._)

Status	ICD-O-3	Term
New term	9085/3	Mixed teratoma- <b>yolk sac tumor</b> (C64.9) <b>Polyembryoma (C62._)</b> <b>Diffuse embryoma (C62._)</b> Mixed teratoma and yolk sac tumour, <b>prepubertal-type (C62._)</b>
New code and term	<b>9086/3</b>	<b>Germ cell tumours with associated haematological malignancy (C37.9)</b>
New behavior code and term	9104/3	Placental site trophoblastic tumour <b>of the testis (C62._)</b>
New term	9110/3	Adenocarcinoma of <b>rete ovarii (C56.9)</b> Adenocarcinoma, <b>HPV-independent</b> , mesonephric type (C53._)
New code and term	<b>9111/3</b>	<b>Mesonephric-like adenocarcinoma (C54._, C56.9)</b>
New term	9120/3	<b>Postradiation</b> angiosarcoma (C50._) <b>Epithelioid</b> angiosarcoma (C50._, C60-C68)
Behavior code change (1→3)	9133/3	Epithelioid hemangioendothelioma (C30.0, C31._, C44._, C40._, C41._, C47._, C49._)
New term	9133/3	Epithelioid hemangioendothelioma <b>with WWTR1-CAMTA1 fusion (C47._, C49._)</b> Epithelioid hemangioendothelioma <b>with YAP1-TFE3 fusion (C47._, C49._)</b>
New code and term	<b>9137/3</b>	<b>Pulmonary artery intimal sarcoma (C34._)</b> <b>Intimal sarcoma (C34._, C47._, C49._)</b>
New term	9170/3	<b>Diffuse</b> lymphangiomatosis (C34._)
New behavior code and term	9174/3	Lymphangioma <b>leiomyomatosis (C34._)</b>
New term	9180/3	<b>Extraskkeletal</b> osteosarcoma (C47._, C49._)
New term	9184/3	<b>Secondary</b> osteosarcoma (C40._, C41._)
New term	9187/3	Low-grade <b>central / intramedullary</b> osteosarcoma (C40._, C41._)
New term	9220/3	Chondrosarcoma, <b>grade 2/3</b> (C12.9, C13._, C14._, C32._, C33.9, C41.0, C41.1)
New code and term	<b>9222/1</b>	<b>Chondrosarcoma, grade 1 (C12.9, C13._, C14._, C32._, C33.9, <del>C41.0, C41.1</del>)</b>
New code and term	<b>9222/3</b>	<b>Chondrosarcoma, grade 1 (C40._, C41._)</b>
New term	9231/3	<b>Extraskkeletal</b> myxoid chondrosarcoma ( <b>C47._, C49._</b> )
New term	9270/3	<b>Sclerosing</b> odontogenic carcinoma (C41.0, C41.1)
New behavior code and term	9302/3	Ghost cell odontogenic <b>carcinoma</b> (C41.0, C41.1)
New term	9330/3	<b>Odontogenic sarcomas</b> (C41.0, C41.1)
Behavior code change (1→3)	9341/3	Clear cell odontogenic tumor (C41.0, C41.1)
New behavior code and term	9341/3	Clear cell odontogenic <b>carcinoma</b> (C41.0, C41.1)

Status	ICD-O-3	Term
New code and term	9366/3	Round cell sarcoma with EWSR1-non-ETS fusions (C40._, C41._, C47._, C49._)
New code and term	9367/3	CIC-rearranged sarcoma (C40._, C41._, C47._, C49._)
New code and term	9368/3	Sarcoma with BCOR genetic alterations (C40._, C41._, C47._, C49._)
New term	9370/3	Poorly differentiated chordoma (C40._, C41._)
New code and term (revised)	9385/3	Diffuse midline glioma, H3 K27-altered M-mutant (C71._) Diffuse hemispheric glioma, H3 G34-mutant (C71._) Diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype (C71._) Infant-type hemispheric glioma (C71._)
New behavior code and term	9391/1	Sellar ependymoma (C75.1) [nonreportable]
New term	9391/3	Ependymoma, NOS (C57._) Supratentorial ependymoma, NOS (C71._) Posterior fossa ependymoma, NOS (C71._) Spinal ependymoma, NOS (C71._, C72.0)
New code and term	9396/3	Ependymoma, RELA fusion-positive (C71._) Supratentorial ependymoma, ZFTA fusion-positive / YAP1 fusion-positive (C71._) Posterior fossa group A (PFA) / group B (PFB) ependymoma (C71._) Spinal ependymoma, MYCN-amplified (C71._, C72.0)
New term (revised)	9400/3	Diffuse astrocytoma, IDH-mutant, grade 2 / <del>IDH-wildtype</del> (C71._)
New term (revised)	9401/3	Anaplastic astrocytoma, IDH-mutant, grade 3 / <del>IDH-wildtype</del> (C71._)
New behavior code and term	9421/3	High-grade astrocytoma with piloid features (C71._)
New term	9424/3	Anaplastic pleomorphic xanthoastrocytoma (C71._)
New term	9430/3	Astroblastoma, MN1-altered (C71._)
New term	9440/3	Epithelioid glioblastoma (C71._)
New term	9440/3	Glioblastoma, IDH-wildtype (C71._)
New code and term	9445/3	Glioblastoma, IDH-mutant (C71._) Astrocytoma, IDH-mutant, grade 4 (C71._)
New term (revised)	9450/3	Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, grade 2 (C71._)
New term (revised)	9451/3	Anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted, grade 3 (C71._)
New term	9470/3	Medulloblastoma, classic (C71._) Medulloblastoma, histologically defined (C71._)

Status	ICD-O-3	Term
New term	9471/3	Medulloblastoma, <b>SHH-activated and TP53-wildtype (C71._)</b>
New term (revised)	9473/3	<b>CNS embryonal tumour, NEC/NOS (C71._)</b>
New code and term	<b>9475/3</b>	<b>Medulloblastoma, WNT-activated(C71._)</b>
New code and term	<b>9476/3</b>	<b>Medulloblastoma, SHH-activated and TP53-mutant (C71._)</b>
New code and term	<b>9477/3</b>	<b>Medulloblastoma, non-WNT/non-SHH (C71._)</b> <b>Medulloblastoma, group 3 / group 4 (C71._)</b>
New code and term	<b>9478/3</b>	<b>Embryonal tumour with multilayered rosettes, C19MC-altered (C71._)</b> <b>Embryonal tumour with multilayered rosettes, NOS (C71._)</b>
New term	9480/3	<b>Primary intracranial sarcoma, DICER1-mutant (C71._)</b>
New term	9490/3	Ganglioneuroblastoma, <b>nodular</b> (C74.1)
New term	9490/3	Ganglioneuroblastoma, <b>intermixed</b> (C74.1)
New term	9500/3	<b>CNS neuroblastoma, FOXR2-activated (C71._)</b> <b>CNS tumour with BCOR internal tandem duplication (C71._)</b>
New term	9508/3	<b>CNS embryonal tumour with rhabdoid features (C71._)</b>
New behavior code and term	9509/3	<b>Diffuse leptomeningeal</b> glioneuronal tumor (C71._)
New term	9540/3	MPNST with <b>perineurial differentiation (C72._)</b>
New code and term	<b>9542/3</b>	<b>Epithelioid malignant peripheral nerve sheath tumour (C44._, C47._, C49._)</b>
New behavior code and term	9591/1	<b>Monoclonal B-cell lymphocytosis, non-CLL-type</b>
New behavior code and term	9673/1	<b>In situ</b> mantle cell neoplasia
New term	9673/3	<b>Conventional</b> mantle cell lymphoma <b>Leukaemic non-nodal</b> mantle cell lymphoma
New behavior code and term	9680/1	EBV-positive mucocutaneous ulcer
New term	9680/3	Diffuse large B-cell lymphoma (DLBCL), <b>Germinal centre B-cell subtype</b>
New term	9680/3	Diffuse large B-cell lymphoma (DLBCL), <b>Activated B-cell subtype</b>
New term	9680/3	<b>Fibrin-associated</b> diffuse large B-cell lymphoma
New term	9680/3	<b>High-grade</b> B-cell lymphoma with <b>MYC and BCL2 and/or BCL6 rearrangements</b>
New term	9680/3	<b>High-grade</b> B-cell lymphoma, NOS
New term	9680/3	<b>Vitreoretinal</b> lymphoma (C69.2)

Status	ICD-O-3	Term
New term	9687/3	Burkitt-like lymphoma <b>with 11q aberration</b> <b>Acute leukaemia</b> , Burkitt type <b>Endemic</b> Burkitt lymphoma <b>Sporadic</b> Burkitt lymphoma <b>Immunodeficiency-associated</b> Burkitt lymphoma
New term	9690/3	<b>Testicular</b> follicular lymphoma <b>Paediatric-type</b> follicular lymphoma
New behavior code and term	9695/1	<b>In situ</b> follicular neoplasia
New term	9695/3	<b>Duodenal-type</b> follicular lymphoma
New term	9698/3	<b>Large B-cell lymphoma with IRF4 rearrangement</b>
New term	9699/3	<b>Primary choroidal</b> lymphoma (C69.3)
New behavior code and term	9702/1	<b>Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract</b>
New term	9702/3	<b>Follicular</b> T-cell lymphoma <b>Nodal</b> peripheral T-cell lymphoma <b>with T follicular helper phenotype</b>
Behavior code change (3→1)	9709/1	Primary cutaneous CD4-positive small/medium T-cell lymphoproliferative disorder
New term	9709/3	Primary cutaneous <b>acral</b> CD8-positive T-cell lymphoma
New code and term	<b>9715/3</b>	<b>Anaplastic large cell lymphoma, ALK-negative [originally 9702/3]</b> <b>Breast implant-associated anaplastic large cell lymphoma</b>
New term	9717/3	<b>Monomorphic epitheliotropic</b> intestinal T-cell lymphoma
Behavior code change (3→1)	9718/1	Lymphomatoid papulosis (C44._)
Behavior code change (3→1)	9725/1	Hydroa vacciniforme-like lymphoproliferative disorder
New behavior code and term	9738/1	HHV8-positive <b>germinotropic lymphoproliferative disorder</b>
New code and term	<b>9749/3</b>	<b>Erdheim-Chester disease</b>
Behavior code change (3→1)	9751/1	Langerhans cell histiocytosis, NOS Langerhans cell histiocytosis, monostotic Langerhans cell histiocytosis, polystotic
New behavior code and term	9761/1	<b>IgM monoclonal gammopathy of undetermined significance</b>
New term	9765/1	<b>Non-IgM</b> monoclonal gammopathy of undetermined significance
New term	9766/1	Lymphomatoid granulomatosis, <b>grade 1, 2</b>
New behavior code and term	<b>9766/3</b>	<b>Lymphomatoid granulomatosis, grade 3</b>



Status	ICD-O-3	Term
New term	9769/1	Light chain and <b>heavy chain</b> deposition diseases <b>Monoclonal</b> immunoglobulin deposition diseases
New term	9807/3	Mixed-phenotype acute leukaemia with t(v; 11q23.3); <b>KMT2A</b> -rearranged
New term	9811/3	B-lymphoblastic leukaemia/lymphoma <b>with iAMP21</b>
New term	9813/3	B-lymphoblastic leukaemia/lymphoma with t(v; 11q23.3); <b>KMT2A</b> -rearranged
New code and term	<b>9819/3</b>	<b>B-lymphoblastic leukaemia/lymphoma, BCR-ABL1-like</b>
New behavior code and term	9823/1	<b>Monoclonal</b> B-cell lymphocytosis, <b>CLL-type</b>
New term	9840/3	<b>Pure</b> erythroid leukaemia
New term	9869/3	AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); <b>GATA2, MECOM</b>
New code and term	<b>9877/3</b>	<b>AML with mutated NPM1</b> [originally 9861/3]
New code and term	<b>9878/3</b>	<b>AML with biallelic mutation of CEBPA</b> [originally 9861/3]
New code and term	<b>9879/3</b>	<b>AML with mutated RUNX1</b>
New term	9897/3	AML with t(9;11)(p21.3;q23.3); <b>KMT2A-MLLT3</b> AML with t(9;11)(p22;q23); <b>KMT2A-MLLT3</b>
New code and term	<b>9912/3</b>	<b>AML with BCR-ABL1</b>
New term	9966/3	Myeloid/ <b>lymphoid</b> neoplasms with PDGFRB
New code and term	<b>9968/3</b>	<b>Myeloid/lymphoid neoplasms with PCM1-JAK2</b>
Behavior code change (3→1)	9971/1	Polymorphic PTLD
New term	9980/3	<b>Myelodysplastic syndrome with single lineage dysplasia</b>
New term	9982/3	<b>Myelodysplastic/myeloproliferative</b> neoplasm with ring siderolasts and thrombocytosis <b>Myelodysplastic syndrome</b> with ring sideroblasts and <b>single lineage dysplasia</b>
New term	9983/3	<b>Myelodysplastic syndrome</b> with excess blasts
New term	9985/3	<b>Myelodysplastic syndrome with multilineage dysplasia</b>
New code and term	<b>9993/3</b>	<b>Myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia</b>

說明：綠色網底表示為本次新增編碼或增修敘述。